echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > New anti-AIDS drug Selzentry goes on sale next month

    New anti-AIDS drug Selzentry goes on sale next month

    • Last Update: 2020-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Selzentry, a new anti-AIDS drugPfizer, has been approved by the U.SFDA and will go on sale next monthSelzentry is the first new anti-AIDS drug developed since 2003 and works by blocking the main pathway of HIV into white blood cellsThe FDA stressed that the drug is intended for patients who have developed resistance to other anti-AIDS drugs or have little effect with other drugs, not patients who have just been diagnosedAt the same time, the FDA said the drug'sadverse reactionsmore serious, including liver orheartdamage, other infections or an increased risk of cancerTo that end, the FDA asked Pfizer to conduct a follow-up study of the drug's side effects(Wang Hai)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.